Food Allergy Market Size and Trend Report including Marketed and Pipeline Drug Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030
The food allergy market was valued at $213.9 million in 2020 globally and is forecast to grow at a CAGR of more than 28% during the forecast period. Food allergy (FA) is defined as an adverse immunologic response to food. While any food can cause an adverse reaction, eight types of food allergens account for the majority of all reactions: eggs, milk, peanuts, tree nuts, fish, shellfish, wheat, and soybeans.
FA is reproducible each time the food is ingested but is often not dose-dependent. It is commonly associated with cutaneous and gastrointestinal reactions. The food allergy market lacks a curative agent, with the only available treatments being antihistamines or epinephrine usage for accidental exposure. The food allergy pipeline consists of 31 drugs across all stages of development, with nine drugs expected to launch by 2030.
Food Allergy Market Overview
For more insights on this report, download a free report sample
What are the key trends in the food allergy market?
Historically, the FA market has seen a lack of R&D. The market was focused on providing symptomatic relief, resulting in the use of off-label drugs such as antihistamines and epinephrine. Additionally, oral immunotherapy (OIT) is the most commonly used treatment to raise the threshold dose for a food allergen and protect allergy patients against accidental ingestion of the allergen.
What are the classifications in the food allergy market?
The classifications in the food allergy market are immunoglobulin E (IgE)-mediated, cell-mediated (non-IgE-mediated), or both IgE- and cell-mediated mechanisms (mixed IgE- and non-IgE-mediated). IgE-mediated allergic responses are the most common type of food allergy, with rapid onset of symptoms after ingestion. In the case of non-IgE-mediated allergic responses, the symptoms are typically delayed for hours, while for mixed IgE- and non-IgE-mediated allergic responses, symptoms appear several hours after the ingestion of the food.
What are the key treatments for food allergy?
The key treatments for food allergy are mild or moderate and severe. In mild or moderate treatment, antihistamines block the effects of histamine, a chemical that is responsible for the majority of allergic reactions. In the severe treatment, epinephrine (adrenaline) constricts the blood vessels to counteract the effects of low blood pressure and relaxes the airways to ease breathing difficulties.
What are the key pipeline products in the food allergy market?
The key pipeline products in the food allergy market are allergy therapeutics for milk allergy, peanut allergy, food allergy, and eosinophilic esophagitis (EoE). The majority of products in development are for peanut allergy, followed by EoE and FA.
Food Allergy Market by Pipeline Products
To know more about key pipeline products, download a free report sample
What are the routes of administration in the food allergy market?
The routes of administration in the food allergy market are oral, intravenous, subcutaneous, and intradermal and cutaneous. Oral administration is the most frequently utilized route of administration for products in the FA pipeline.
Food Allergy Market by Routes of Administration
To know more about routes of administration, download a free report sample
Who are the key players in the food allergy market?
Some of the key players in the food allergy market are Aimmune Therapeutics, Dr. Falk Pharma GmbH, Sanofi, DBV Technologies SA, Novartis, AstraZeneca, Regeneron Pharmaceuticals Inc, Roche/Genentech, Camallergy (Cambridge Allergy Ltd), ALK-Abello AS, and Ellodi Pharmaceuticals.
Market report scope
Market size (Year – 2020) | $213.9 million |
Growth rate | CAGR of >28% |
Forecast period | 2020-2030 |
Classifications | Immunoglobulin E (IgE)-Mediated, Cell-Mediated (Non-IgE-Mediated), or Both Ige- and Cell-Mediated Mechanisms (Mixed Ige- and Non-Ige-Mediated) |
Key treatments | Mild or Moderate and Severe |
Key pipeline products | Milk Allergy, Peanut Allergy, Food Allergy, and Eosinophilic Esophagitis (EoE) |
Routes of administration | Oral, Intravenous, Subcutaneous, and Intradermal and Cutaneous |
Key players | Aimmune Therapeutics, Dr. Falk Pharma GmbH, Sanofi, DBV Technologies SA, Novartis, AstraZeneca, Regeneron Pharmaceuticals Inc, Roche/Genentech, Camallergy (Cambridge Allergy Ltd), ALK-Abello AS, and Ellodi Pharmaceuticals |
This report provides:
- Overview of FA including etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Key topics including the current treatment and pipeline therapies, trends, clinical trials, unmet needs, challenges and opportunities, and market analysis.
- Analysis of the current and future market competition in FA therapeutics market.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the FA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the FA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track drug sales in the FA therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Players
Table of Contents
Frequently Asked Questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
GDPR + CCPA Compliant
Personal and transaction information are kept safe from unauthorised use.